

REC Ref.	IRAS No.	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
18/NW/0107	236834	PHIL evaluation in the endovascular treatment of intracranial cerebral ArterioVenous Malformation	Number Agreed	6	6	Date Agreed	31/08/2019	0	26/10/2018	0	Withdrawn By Sponsor
18/LO/0666	242700	Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).	Number Agreed	2	2	Date Agreed	01/07/2020	2	22/10/2018	2	Recruitment Finished
18/LO/1063	236384	The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study-Actellion - AC-065A308	Range Agreed	1	3	Date Agreed	29/12/2018	2	29/12/2018	2	Recruitment Finished
17/LO/0380	218003	PET-LONGITUDINAL SUBSTUDY ASSOCIATED WITH: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODRONTAL TO MILD ALZHEIMER'S DISEASE	Number Agreed	1	1	Date Agreed	31/07/2018	1	19/06/2018	1	Recruitment Finished
17/NE/0151	223815	Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia (SGI-110-06).	Number Agreed	2	2	Date Agreed	31/12/2018	0	14/09/2018	0	Withdrawn By Sponsor
17/LO/1695	234684	A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Medicated Gene Transfer of Human Factor VIII in Haemophilia A Patients with Residual FVIII Levels ≥ 1 IU/dl Receiving Prophylactic FVIII Infusions.	Number Agreed	1	2	Date Agreed	01/06/2018	3	01/06/2018	3	Recruitment Finished
17/SC/0394	229032	An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib.	Number Agreed	3	3	Date Agreed	31/12/2018	4	12/12/2018	4	Recruitment Finished
17/EE/0026	220207	A Prospective, Randomized, Controlled, Multi-Center Clinical Study of the ACRYSO IQ Extended Depth of Focus (EDF) IOL	Number Agreed	10	10	Date Agreed	30/07/2018	11	30/07/2018	11	Recruitment Finished
17/EM/0236	221138	Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in Parkinson's Disease (PD).	Number Agreed	4	4	Date Agreed	31/07/2018	3	31/07/2018	3	Recruitment Finished
17/EE/0177	220722	A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (Svd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).	Number Agreed	3	3	Date Agreed	01/06/2020	7	26/09/2018	7	Recruitment Finished
17/EM/0154	222912	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)	Number Agreed	4	4	Date Agreed	01/12/2018	5	01/12/2018	5	Recruitment Finished

17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	Number Agreed	4	4	Date Agreed	31/05/2018	10	31/05/2018	10	Recruitment Finished
17/LO/0863	228208	EU- Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy use in secondary and primary care - Da Vinci	Number Agreed	45	45	Date Agreed	30/04/2018	43	20/11/2018	43	Recruitment Finished
17/SC/0122	224090	AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children	Number Agreed	12	12	Date Agreed	01/12/2017	12	01/12/2018	15	Recruitment Finished
17/SC/0291	226509	The DEFINE PCI study: Physiologic assessment of coronary stenosis following PCI.	Number Agreed	20	20	Date Agreed	31/03/2019	7	28/01/2019	7	Withdrawn By Sponsor
17/EM/0116	222773	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off"	Number Agreed	4	4	Date Agreed	30/06/2018	0	30/06/2018	0	Recruitment Finished
17/NW/0180	220257	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy.	Number Agreed	2	2	Date Agreed	28/02/2018	1	08/08/2018	1	Recruitment Finished
17/NW/0175	222859	A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult patients with Persistent/Chronic Immune Thrombocytopenia	Number Agreed	1	1	Date Agreed	20/12/2017	2	17/05/2018	2	Recruitment Finished
17/LO/0304	222475	A double-blind, randomised, placebo-controlled, parallel-group, phase 2, dose-ranging trial to evaluate the efficacy, safety and tolerability of oral Litoxetine 10mg, 20mg and 40mg twice daily (BID) versus placebo in women with mixed urinary continence	Number Agreed	10	12	Date Agreed	30/05/2018	0	30/05/2018	0	Withdrawn By Sponsor
17/EE/0081	219405	An open label, single arm pilot study of OncoSilâ„¸, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies.	Number Agreed	2	2	Date Agreed	01/06/2020	6	26/06/2018	6	Recruitment Finished
17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine	Number Agreed	1	1	Date Agreed	31/12/2018	1	31/12/2018	1	Recruitment Finished
16/NE/0067	199159	A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson's Disease.	Number Agreed	4	4	Date Agreed	31/12/2017	6	03/12/2018	6	Recruitment Finished
16/EE/0357	206501	Efficacy and safety of opicapone in clinical practice in Parkinson's Disease patients with wearing-off motor fluctuations	Number Agreed	04/01/1900	04/01/1900	Date Agreed	30/11/2017	8	18/10/2018	8	Recruitment Finished
16/LO/1891	213918	A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepatitis (AH)	Number Agreed	01/01/1900	01/01/1900	Date Agreed	15/12/2017	2	28/05/2018	2	Recruitment Finished
16/LO/0542	201528	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)	Number Agreed	04/01/1900	04/01/1900	Date Agreed	01/05/2018	2	01/05/2018	2	Recruitment Finished
17/LO/0052	212454	Evaluation of Uterine Patency following Sonography-guided Transcervical Ablation of Fibroids	Number Agreed	10/01/1900	10/01/1900	Date Agreed	01/11/2018	9	28/09/2018	9	Recruitment Finished
16/LO/1244	200385	A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy	Number Agreed	03/01/1900	03/01/1900	Date Agreed	31/03/2019	3	12/11/2018	4	Recruitment Finished
16/WM/0271	200160	Prospective, Single-Arm, Multi-Centre Study to Evaluate the Contour Neurovascular Systemâ„¸	Number Agreed	10/01/1900	10/01/1900	Date Agreed	07/07/2021	5	12/09/2018	5	Recruitment Finished

14/LO/0344	140294	A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease	Number Agreed	01/01/1900	01/01/1900	Date Agreed	31/12/2017	2	20/04/2018	2	Recruitment Finished
16/LO/0675	147355	A PHASE 2, INTERNATIONAL, MULTICENTER, RANDOMIZED, OPENLABEL, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) ALONE AND IN COM+H768BINATION WITH DURVALUMAB (MEDI4736) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTION OR DECITABINE	Number Agreed	03/01/1900	03/01/1900	Date Agreed	31/10/2019	0	03/07/2018	0	Withdrawn By Sponsor
16/LO/0443	197312	A multicentre, open-label, multiple-dose study to evaluate the safety, tolerability and efficacy of UCB7665 in subjects with primary immune thrombocytopenia (ITP)	Number Agreed	01/01/1900	01/01/1900	Date Agreed	30/12/2018	1	30/12/2018	1	Recruitment Finished
16/YH/0083	192397	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma.	Number Agreed	10/01/1900	10/01/1900	Date Agreed	30/04/2019	11	26/11/2018	11	Recruitment Finished
16/LO/0118	191634	Valiant Evo International Clinical Trial	Number Agreed	04/01/1900	04/01/1900	Date Agreed	30/07/2018	5	10/05/2018	5	Recruitment Finished
15/WM/0453	172946	A Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 versus Fulvestrant in Postmenopausal Women with estrogen receptor positive HER-2 negative Primary Breast Cancer	Number Agreed	05/01/1900	05/01/1900	Date Agreed	30/11/2018	2	30/11/2018	2	Recruitment Finished
16/YH/0081	186580	A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis.	Number Agreed	01/01/1900	01/01/1900	Date Agreed	24/04/2018	0	24/04/2018	0	Recruitment Finished
16/NE/0023	190035	A Phase III, Multi-centre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study with Open-Label Extension of Crenezumab in Patients with Prodromal-to-Mild Alzheimer's Disease	Number Agreed	08/01/1900	08/01/1900	Date Agreed	01/08/2018	8	01/08/2018	8	Recruitment Finished
15/SC/0616	188838	An exploratory, randomised, double-blind, placebo-controlled study of the effects of dupilumab on airway inflammation of adults with persistent asthma	Number Agreed	03/01/1900	03/01/1900	Date Agreed	27/07/2017	1	17/10/2018	1	Recruitment Finished
15/YH/0434	185622	Dose Optimization Study of Idelalisib in Follicular Lymphoma and Small Lymphocytic Lymphoma.	Number Agreed	02/01/1900	02/01/1900	Date Agreed	01/06/2019	0	01/08/2018	0	Withdrawn By Host
16/EM/0259	165592	A prospective, multicentre, open-label, randomized, active-controlled, 3 parallel groups, phase 2 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), versus masitinib alone, versus Best Supportive Care, in third or fourth line treatment of patients with metastatic colorectal cancer	Number Agreed	03/01/1900	03/01/1900	Date Agreed	06/11/2018	3	06/11/2018	3	Recruitment Finished
14/LO/1559	152866	Sorin Universal REgistry on Aortic Valve Replacement	Number Agreed	20/01/1900	09/02/1900	Date Agreed	01/09/2018	40	01/09/2018	40	Recruitment Finished
15/NE/0167	171524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Number Agreed	06/01/1900	06/01/1900	Date Agreed	25/11/2019	2	12/09/2018	2	Recruitment Finished
15/NW/0592	185435	A randomised, double-blind, double-dummy, placebo-controlled, parallel-group multi-centre clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell function	Number Agreed	01/01/1900	01/01/1900	Date Agreed	27/11/2018	1	27/11/2018	1	Recruitment Finished

15/LO/1641	180563	Global Clinical Study of Renal Denervation with the Symplicity Spyralâ„¸ multi-electrode renal denervation system in Patients with Uncontrolled Hypertension in the Absence of Antihypertensive Medications	Range Agreed	05/01/1900	10/01/1900	Date Agreed	01/11/2019	16	04/06/2018	16	Recruitment Finished
15/LO/1640	180561	Global Clinical Study of Renal Denervation with the Symplicity Spyralâ„¸ multi-electrode renal denervation system in patients with uncontrolled hypertension on standard medical therapy	Number Agreed	05/01/1900	05/01/1900	Date Agreed	31/12/2019	5	03/05/2018	5	Recruitment Finished
14/YH/1153	159477	An Open-Label, Extension Study of the Effects of Leuco-methylthionium bis (hydromethanesulfonate) in Subjects with Alzheimerâ€™s Disease or Behavioral Variant Frontotemporal Dementia	Number Agreed	10/01/1900	10/01/1900	Date Agreed	10/10/2018	14	10/10/2018	14	Recruitment Finished
11/SW/0001		T-Doc air charged catheter evaluation	Number Agreed	30/01/1900	30/01/1900	Date Agreed	06/07/2018	0	06/07/2018	0	Recruitment Finished
10/H0801/67	145462	Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasibility Study	Number Agreed	15/01/1900	15/01/1900	Date Agreed	31/07/2018	4	11/05/2018	4	Recruitment Finished
11/EE/0256	185421	Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	Number Agreed	10/01/1900	10/01/1900	Date Agreed	31/12/2016	6	01/06/2018	6	Withdrawn By Sponsor
15/LO/1538	188226	A study to evaluate the effectiveness and safety of Exablate transcranial MRgFUS thalamotomy treatment of medication refractory essential tremor subjects	Number Agreed	10/01/1900	10/01/1900	Date Agreed	13/02/2019	17	13/02/2019	17	Recruitment Finished
14/LO/0865	156211	A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy	Number Agreed	05/01/1900	05/01/1900	Date Agreed	01/04/2018	8	01/04/2018	8	Recruitment Finished
16/EE/0386	208339	A Multicentre, Randomised, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer	Number Agreed	05/01/1900	05/01/1900	Date Agreed	31/01/2019	5	31/01/2019	5	Recruitment Finished